Archives

by in
Entry Author Date Location
5 Things Biotechs Should Do to Take Advantage of The Boom 09/05/13 New York
Syndax Pockets $26.6M For Final Stage Push With Cancer Drug 08/27/13 Boston
Why Good Drugs Sometimes Fail: The Bexxar Story 08/26/13 National
Ophthotech Eyes $85M IPO With Late-Stage Clinical Trial in Sight 08/15/13 New York
Six Reasons Why Giving Scientists Big Bonuses Won’t Fix Pharma R&D 08/12/13 National
Ensemble Reels in Novartis to Develop Oral, Mid-Sized Inflammation Drugs 08/06/13 Boston
A Band of Postdocs Pursues a New York Biotech Dream in Harlem 08/05/13 New York
Agios Prices Upsized IPO Above Range, Preps For Nasdaq Debut 07/24/13 Boston
SMC Bio Looks to Heal Bones With Carbohydrates, Not Stem Cells 07/18/13 San Francisco
Why I Won’t Cheer If Onyx Pharma Is Sold for Megabucks 07/15/13 National
Forma, CRT Deal Part of Broader Research Initiative 07/09/13 Boston
Baseball and Biopharma: More Alike Than You Might Realize 07/03/13 Seattle
Q2 Review: Top San Francisco Stories from April, May, and June 07/01/13 San Francisco
Bayer Joins with Seattle Genetics in Antibody-Drug Conjugate Deal 06/25/13 Seattle
Immune Design, NY Non-Profits Team Up to Boost Cancer Drugs 06/12/13 Seattle
Agios Files For IPO With Plans to Raise $86M 06/11/13 Boston
Profiles in Long-Termism: Sarepta Therapeutics CEO Chris Garabedian 06/10/13 National
CytomX Snags $25M From Pfizer to Make Souped-Up Antibodies 06/06/13 San Francisco
ASCO Wrap-Up: Cancer News from the West Coast 06/04/13 National
Biodesix’s VeriStrat Test for Cancer Treatment Passes Phase 3 Trial 06/03/13 Boulder/Denver
Merck Joins Bristol, Genentech in Great Cancer Immunotherapy Race 06/02/13 New York
Plexxikon Leadership Duo, Peter Hirth and Kathy Glaub, Exit Daiichi 05/31/13 San Francisco
Oncothyreon Nabs $10M, Pays $10M, For Array Biopharma Cancer Drug 05/30/13 Seattle
UT Horizon Fund Aims to Build, and Capture, Value from Its Startups 05/21/13 Texas
Genentech Follows Fast at ASCO as Cancer Immunotherapy Picks Up 05/15/13 San Francisco
Genentech Cancer Antibody, Son of Rituxan, Nails Pivotal Study 05/15/13 San Francisco
Ensysce’s Bet: Combining Two Risky Drug Technologies That Add Up 05/09/13 Texas
San Diego Life Sciences Roundup: Topera, Afraxis, Trovagene, & More 05/03/13 San Diego
Aveo’s Stock Plunges As Day of Reckoning Nears For Cancer Drug 04/30/13 Boston
Meet Ben Fidler, Xconomy’s New East Coast Biotech Editor 04/15/13 New York
Page 3 of 16 « previous page · next page »